Your email has been successfully added to our mailing list.

×
0.0361067503924646 0.0361067503924646 -0.010989010989011 -0.010989010989011 -0.010989010989011 0.0204081632653061 0.0204081632653061 0.0204081632653061
Stock impact report

Akcea Therapeutics genetic disease treatment gets FDA approval [Reuters (UK)]

AKCEA THERAPEUTICS (AKCA) 
Last akcea therapeutics earnings: 2/25 04:05 pm Check Earnings Report
Company Research Source: Reuters
Akcea Therapeutics genetic disease treatment gets FDA approval | Reuters 2 Min Read (Reuters) - Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. Akcea’s once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy. Polyneuropathy, a symptom of the disease, is the simultaneous malfunction of peripheral nerves in the body resulting in tingling, numbness and kidney dysfunction. Tegsedi belongs to a class of drugs that uses the Nobel-prize winning RNA interference mechanism to manipulate ribonucleic acid, which interferes with or “silences” targeted genes and stops the formation of proteins that can cause diseases. Tegsedi’s approval in the United States comes nearly three months after its approval in Europe. Based on the U.S. approval of Tegsedi, Ionis will receive a $50 million milestone payment and both the compa Show less Read more
Impact Snapshot
Event Time:
AKCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AKCA alerts
Opt-in for
AKCA alerts

from News Quantified
Opt-in for
AKCA alerts

from News Quantified